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Abstract
Background: Endostatin is a C-terminal fragment of collagen XVIII which is a component of
basement membranes with the structural properties of both collagens and proteoglycans.
Endostatin has a major role in angiogenesis which is intimately associated with bone development
and remodeling. Signaling between the endothelial cells and the bone cells, for example, may have
a role in recruitment of osteoclastic precursor cells. Our study aims at exploring a possibility that
endostatin, either as a part of basement membrane or as a soluble molecule, may control
osteoclastogenesis and osteoclastic bone resorption in vitro.
Methods: Rat pit formation assay was employed in order to examine the effect of endostatin alone
or in combination with vascular endothelial growth factor-A (VEGF-A) on bone resorption in vitro.
Effect of these agents on osteoclast differentiation in vitro was also tested. Osteoclastogenesis and
the number of osteoclasts were followed by tartrate resistant acid phosphatase (TRACP) staining
and resorption was evaluated by measuring the area of excavated pits.
Results: Endostatin inhibited the VEGF-A stimulated osteoclastic bone resorption, whereas
endostatin alone had no effect on the basal resorption level in the absence of VEGF-A. In addition,
endostatin could inhibit osteoclast differentiation in vitro independent of VEGF-A.
Conclusion: Our in vitro data indicate that collagen XVIII/endostatin can suppress VEGF-A induced
osteoclastic bone resorption to the basal level. Osteoclastogenesis is also inhibited by endostatin.
The regulatory effect of endostatin, however, is not critical since endostatin alone does not modify
the basal bone resorption.
Background
The development and continuous remodeling of the skel-
eton demand a tightly regulated balance between the
bone-forming and bone-resorbing processes. One of the
key components of bone remodeling is constant develop-
ment of vasculature. Vasculature is required for transport
of nutrients and precursor cells, such as precursors of
chondroclasts and osteoclasts, to the renewing bone tis-
sue. Angiogenesis has also been shown to be crucial for
the replacement of cartilage by bone during skeletal
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tor-A (VEGF-A), produced by hypertrophic chondrocytes
during endochondral bone formation, stimulates control-
led invasion of chondroclasts into the cartilage [1,2].
VEGF-A is also a chemoattractant for endothelial cells and
regulates the growth plate vascularisation of metaphyseal
bone.
Invasion of osteoclasts into hypertrophic cartilage
requires presence of VEGF-A [3] which binds with high
affinity to two tyrosine kinase receptors, Flt-1 and Flk-1
[4]. VEGF-A may attract osteoclast precursor cells that are
recruited from hematopoietic tissue. It has been reported
that VEGF-A is potentially a monocyte chemoattractant
[5]. Monocytes express Flt-1, but not Flk-1 [6]. In response
to VEGF-A, macrophages derived from Flt-1 mutant mice
indicated deranged chemotaxis [7] demonstrating that
Flt-1 may mediate the migration of monocyte/macro-
phage lineages. Mature osteoclasts have been shown to
express Flt-1 and Flk-1 on their cells surface [1,8-12] and
both of these receptors may mediate the VEGF-A effect on
bone formation and bone resorption [8]. Recently pub-
lished data clearly indicates that VEGF-A is important
both in endochondral and intramembranous ossification
[13,14]. Precise mechanisms of the recruitment of osteo-
clast precursors into the site of bone resorption, however,
remain unclear.
Endostatin, a known antagonist for VEGF-A, is 20 kDa C-
terminal fragment of collagen XVIII found in basal mem-
branes. Endostatin, that binds to αv- and α5-integrins
[15], inhibits endothelial cell proliferation and it may
inhibit angiogenesis and tumor growth [16]. Resorbing
osteoclasts have been shown to express at least αv-
integrins [17-19], creating a potential for endostatin to
control osteoclast function. Role of endostatin on bone
resorption or osteoclast differentiation, however, is not
established.
Aim of our study was to further define possible role of
endostatin and VEGF-A on osteoclasts in vitro. In order to
investigate the direct effects of these angiogenic and
antiangiogenic substances on osteoclast mediated bone
resorption, we used classical resorption pit assay and oste-
oclast differentiation assay of bone marrow hematopoi-
etic stem cells. We were, for the first time, able to
demonstrate that endostatin has a significant regulatory
role on both osteoclastic bone resorption and osteoclas-
togenesis in vitro.
Methods
Osteoclast isolation and culture
The procedure for the isolation and culture of osteoclasts
described earlier by Boyde et al. and by Chambers et al.
[20,21] was modified slightly and has been described in
detail previously [22]. Briefly, mechanically harvested
osteoclasts from the long bones of 1- or 2-day-old
Sprague-Dawley rat pups were allowed to attach to ultra-
sonicated bovine cortical bone slices (0.125 cm2 or 0.5
cm2). After 30 minutes, the nonattached cells were rinsed
away, and the remaining cells on the bone slices were cul-
tured in Dulbecco's modified Eagle's medium (α-MEM)
buffered with 20 mM HEPES and containing 0.84 g of
sodium bicarbonate/liter, 2 mM L-glutamine, 100 IU of
penicillin/ml, 100 µg of streptomycin/ml and 7–10%
heat-inactivated fetal calf serum (FCS), at +37°C (5% CO2
and 95% air). The cells were divided into ten groups: the
control group had α-MEM-FCS as their culture medium
with no added substances (later referred as control), the
VEGF-A-treated cells had 100 ng/ml, 50 ng/ml or 10 ng/
ml VEGF-A in α-MEM-FCS (later referred as VEGF). The
endostatin groups had 0.02, 0.2 or 2 µg/ml endostatin in
α-MEM-FCS (later referred as ENDO) and the last groups
had both VEGF-A and endostatin added into the complete
culture media (later referred as VEGF+ENDO). The last
groups had 100 ng/ml VEGF-A and 2 µg/ml endostatin,
50 ng/ml VEGF-A and 0,2 µg/ml endostatin or 10 ng/ml
VEGF-A and 0,02 µg/ml endostatin. The cells were
allowed to grow for 48 h, after which the bone slices were
fixed with freshly made refrigerated 3% paraformalde-
hyde (PFA) and 2% sucrose in phosphate-buffered saline
(PBS) for 10 minutes at room temperature. The data
shown in this manuscript is gathered from three inde-
pendent experiments, each of which gave identical results.
Osteoclast differentiation assay
The procedure for osteoclast differentiation described ear-
lier by Takahashi et al. [23] was slightly modified. Mouse
(C57BL/6, 8–12 weeks) bone marrow cells were isolated
from mouse long bones by using syringe. After incubation
at +37°C for 2 hours non-attached cells were collected
from petri dish. Mouse bone marrow cells were seeded in
24-well plates containing sonicated cortical bovine bone
slices (0.125–0.5 cm2) at a concentration of 1 × 106 cells/
well. Cells on the bone slices were cultured in four groups:
control, VEGF (100 ng/ml) and ENDO (2 µg/ml) and
VEGF + ENDO respectively. The control group was cul-
tured in α-MEM medium (Sigma, UK) with 10% heat-
inactivated fetal calf serum (FCS), 2 mM L-glutamin, 100
IU/ml penicillin, 10 µg/ml streptomycin and 20 mM
Hepes which medium will be later referred to as α-MEM-
FCS. Cells were cultured in 500 µl α-MEM containing 30
ng/ml RANKL (Peprotech Ec., UK) and 10 ng/ml M-CSF
(R&D Systems). Half of the medium was replaced every
3rd day. Cells were cultured at +37°C (5% CO2, 95% air)
for 7 days, after which the cultures were stopped by fixing
the cells with 3% paraformaldehyde (PFA)/2% sucrose in
PBS.Page 2 of 7
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Bone cells were cultured for 48 hours in resorption pit
assay and 7 days in the differentiation assay. After the cul-
ture period, bone slices were fixed as described above. The
cells were stained for tartrate-resistant acid phosphatase
(TRACP), a commonly accepted marker of osteoclasts
[24] using a Sigma TRACP kit (no. 386-A, Sigma Chemi-
cals, St. Louis, MO) according to the manufacturer's
instructions. To visualize the nuclei, the cells were incu-
bated with the DNA-binding fluorochrome Hoechst
33258 (1 mg/ml stock diluted 1:800 in PBS, Sigma Chem-
ical Co, St. Louis, MO) for 10 minutes at room tempera-
ture. The numbers of multinucleated TRACP-positive cells
on each bone slice were counted, using a Nikon Eclipse
600 microscope and Nikon Plan Fluor 20×/0.50 objective
with an appropriate filterset.
Area measurement of excavated pits
Prior to the staining of the pits, total detachment of the
cells from the bone slices was ensured by wiping the cel-
lular surface of the slices with a soft brush. The pits were
stained with peroxidase-conjugated wheat germ aggluti-
nin-lectin (WGA; 20 µg/ml, Sigma Chemical Co., St.
Louis, MO) for 20 minutes, washed with PBS, and incu-
bated for 5 minutes in diaminobenzidine (0,5 mg/ml)
+0,03% H2O2. Morphometric analysis of the resorption
pits was performed with an MCID image analyzer, utiliz-
ing M2 software (Imaging Research Inc., Brock University,
Ontario, Canada).
Statistical analysis
Data presented are the results of at least two independent
experiments. Values are the mean ± SEM. Significance was
calculated using one-way ANOVA followed by Student's t-
test with statistical package Origin 6.0. The p-values less
than 0.05 were considered as significant.
Results
Bone resorption assay
The number of osteoclasts after 48 hours in each sample
group was counted by analyzing multinuclear TRACP-
positive cells in the resorption assay. No significant differ-
ences in the number osteoclasts were found between the
different groups (Fig 1A) indicating that none of the treat-
ments was toxic to these cells.
The total resorbed area was significantly increased in
response to VEGF-A treatment and the effect was dose
dependent (Fig. 1B). Endostatin alone had no inhibitory
effect on the resorbed area when compared to the basal
level of osteoclastic bone resorption. When both endosta-
tin and VEGF-A were supplemented, the stimulatory effect
by VEGF-A on bone resorption was halted to the basal
level. The resorption activity was even below basal level
with the highest concentrations (p < 0.05 in ctrl vs.
Number of TRACP+ multinuclear cells and the activity of bone r s rption in pit assayFigur  1
Number of TRACP+ multinuclear cells and the activ-
ity of bone resorption in pit assay. Rat bone cells were 
cultured for 48 hours with no added substances (CON-
TROL), vascular endothelial growth factor A (VEGF ng/ml), 
endostatin (ENDO µg/ml) or both VEGF-A and endostatin 
(VEGF ng/ml +ENDO µg/ml). (A) Survival rate of osteo-
clasts after different treatments was measured by counting 
the numbers of TRACP-positive cells with two or more 
nuclei indicating osteoclasts. No significant differences in the 
number of osteoclasts could be seen. (B) Osteoclastic bone 
resorption could be visualized with WGA-lectin stain and 
total resorbed areas from the different cultures were meas-
ured. VEGF-A treatment induced a clear stimulus, whereas 
endostatin caused no effect on the resorbed area. Addition 
of both VEGF-A and endostatin caused a statistically signifi-
cant decrease in the total resorbed area when compared to 
the VEGF-A-induced resorption. (VEGF ng/ml, ENDO µg/
ml)Page 3 of 7
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the VEGF-A-induced stimulatory effect on osteoclastic
bone resorption. These results are also demonstrated in
figure 2 in which representative bone slices are shown.
Osteoclast differentiation
In the presence of RANKL and M-CSF the bone marrow
hematopoietic cells differentiate into osteoclasts which
can be recognized by positive TRACP-stain and multinu-
clear appearance. Since the basal resorption was not
affected by endostatin in the pit assay, we conducted an
assay to investigate if endostatin could inhibit the differ-
entiation of osteoclasts. We added VEGF-A to the medium
containing M-CSF and RANKL in order to achieve maxi-
mal differentiation stimulus (Fig. 3). Endostatin was able
to abolish the maximal osteoclastogenesis and to reduce
the number of TRACP+ cells in the presence of VEGF,
RANKL and M-CSF or RANKL and M-CSF only.
Discussion
Bone remodeling is initiated by recruitment of osteoclast
precursor cells from bone marrow or circulating mono-
cytes. Homing of these precursors through the vascular
wall is required for successful bone turnover. Intimate
contact of the bone remodeling site to adjacent vascular
sinusoids indicates interplay between the vascular
endothelium and the bone cells. Co-culture of osteoblasts
and endothelial cells stimulate the osteoblasts to secrete
VEGF-A and to express RANKL, which is crucial for osteo-
clastogenesis [25]. VEGF-A is a chemoattractant for osteo-
clasts and lack of VEGF-A halts invasion of osteoclasts into
hypertrophic cartilage through an MMP-9 dependent
mechanism [3]. The similar kinetics and signaling path-
ways of RANKL and VEGF-A as chemoattractants differ
from those of M-CSF [26]. The significance of VEGF-A in
osteoclastogenesis is clearly demonstrated in osteo-
petrotic mice with a mutation in the M-CSF gene [27-29].
The mice have severe deficiency of osteoclasts, monocytes,
and peritoneal macrophages. Injections of purified
recombinant human M-CSF (rhM-CSF) compensate for
these deficiencies in the mutant mice [30-33]. Interest-
ingly, a single injection of rhVEGF-A can substitute M-CSF
and cure osteopetrosis [8].
Significance of endostatin in bone has been demonstrated
elegantly in the ex vivo metatarsal model in which fusion
and migration of osteoclast precursors is required for the
osteoclastic bone resorption [26]. Osteoclastic recruit-
ment from periosteum can be inhibited by endostatin,
leading to blocked dissolution of the calcified matrix in
the developing marrow cavity. Endostatin completely
inhibits VEGF-A and placental growth factor-2 mediated
osteoclast invasion but has no effect on RANKL or M-CSF
induced migration. The recruitment and invasion of oste-
oclast precursors can be disturbed by endostatin in the
Typical appearance of the bone slices in the pit assayFigure 2
Typical appearance of the bone slices in the pit assay. 
Rat bone cells were cultured on bovine bone slices with dif-
ferent treatments. After 48 hours, cells were wiped off and 
resorbed bone area was visualized with image analyzer sys-
tem. Bone slices after (A) Control (B) VEGF-A 10 ng/ml (C) 
VEGF-A 50 ng/ml (D) VEGF-A 100 ng/ml (E) Endostatin 0.02 
µg/ml (F) Endostatin 0.2 µg/ml (G) Endostatin 2 µg/ml (H) 
VEGF-A 10 ng/ml and Endostatin 0.02 µg/ml (I) VEGF-A 50 
ng/ml and Endostatin 0.2 µg/ml (J) VEGF-A 100 ng/ml and 
Endostatin 2 µg/ml treatments. Scale bar 100 µm.Page 4 of 7
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invasion of osteoclasts into the marrow cavity of develop-
ing long bones in vivo [8]. In our pit formation assay in
vitro, mature osteoclasts already exist. Still, we see a clear
reduction of VEGF-A-stimulated resorption in the
endostatin treated pit assays. Thus, it is possible that
endostatin may not only limit the migration of osteoclast
precursors, but it may also inhibit the VEGF-A-induced
osteoclast activation. Pufe et al. have detected similar
influence of endostatin on hyaline articular cartilage.
Endostatin alone had no effect on basal levels on the
phosphorylation of ERK1/2, whereas co-incubation with
endostatin blocked VEGF-induced ERK1/2 phosphoryla-
tion in immortalized human chondrocytes (C28/I2)
[34,35].
Osteoclast precursor differentiation into mature osteo-
clasts is disturbed in the absence of VEGF-A [5]. VEGF-A
also aids in the bone-resorbing function of osteoclasts
[8,11]. Nakagawa and co-workers [11] have shown that
the presence of VEGF-A enhances survival of pure rabbit
osteoclasts and increases the resorbed bone area. In our
resorption pit assay containing osteoblasts and osteo-
clasts, however, the number of TRACP-positive cells
remained unchanged (Fig. 1A). The data show that the
increased total resorbed area in our model (Fig. 1B) is not
due to enhanced survival rate. The observed effect is more
likely a result of a direct VEGF-A stimulation on osteoclas-
tic bone resorption.
Combination of RANKL, M-CSF, and VEGF-A activated
intense differentiation of osteoclasts in our study in vitro.
RANKL and VEGF-A stimulate the osteoclast recruitment
through the same signaling pathway [26] and these path-
ways were most likely fully stimulated in our cell cultures.
Endostatin, however, inhibited osteoclastogenesis when
compared to this maximal stimulus (achieved with the
combination of M-CSF, RANKL, and VEGF-A). Interest-
ingly, the inhibitory effect was also seen in the absence of
VEGF-A. This result indicates that inhibition by endosta-
tin cannot be solely explained as an antagonism of VEGF-
A.
Endostatin did not inhibit basal bone resorption in our in
vitro experiments suggesting that regulatory role of
endostatin on osteoclasts may not be critical. In patholog-
ical conditions, however, endostatin may have a signifi-
cant position. Endostatin is normally found in serum
[36,37] and a possible therapeutic role for endostatin has
been studied in cancer with promising results [38-40].
Endostatin could also be considered as a physiological
inhibitor of inflammation induced neovascularization in
arthritis patients. VEGF-A levels are elevated in arthritis
and thus osteoclastic bone resorption is enhanced.
Recently a clinical trial on patients with rheumatoid
arthritis showed increased serum endostatin levels after a
single injection of a TNF-α antibody. In addition,
endostatin overexpression inhibited development of
arthritis in the joints of TNF-transgenic mice [41]. Our in
vitro data support the possibility that endostatin could be
used as a physiological agent to inhibit the osteoclast
activity in inflammatory arthritis. Further in vivo studies in
animal models may be considered to explore that possi-
bility.
Conclusion
Our in vitro data indicate that collagen XVIII/endostatin
can suppress VEGF-A induced osteoclastic bone resorp-
tion to the basal level. Osteoclastogenesis is also inhibited
by endostatin. The regulatory effect of endostatin, how-
ever, is not critical since endostatin alone does not modify
the basal bone resorption.
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The number of TRACP+ multinuclear cellsFigure 3
The number of TRACP+ multinuclear cells. Mouse 
(C57BL/6, 8–12 weeks) bone marrow cells were isolated 
from mouse long bones and seeded in 24-well plates on 
bovine bone slices. Cells on the bone slices were cultured in 
four groups: control, VEGF (100 ng/ml) and ENDO (2 µg/ml) 
and VEGF + ENDO respectively. The control group was cul-
tured in α-MEM with 10% FCS containing 30 ng/ml RANKL 
and 10 ng/ml M-CSF for 7 days, after which the cultures were 
stopped by fixing the cells with 3% paraformaldehyde (PFA)/
2% sucrose in PBS.Page 5 of 7
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